Article
Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.
Pediatric nephrology (Berlin, Germany) - 1 Jan 2017
Stock Johanna, Kuenanz Johannes, Glonke Niklas, Sonntag Joseph, Frese Jenny, Tönshoff Burkhard, Höcker Britta, Hoppe Bernd, Feldkötter Markus, Pape Lars, Lerch Christian, Wygoda Simone, Weber Manfred, Müller Gerhard-Anton, Gross Oliver
Abstract excerpt
BACKGROUND: Patients with autosomal or X-linked Alport syndrome (AS) with heterozygous mutations in type IV collagen genes have a 1-20 % risk of progressing to end-stage renal disease during their lifetime. We evaluated the long-term renal outcome of patients at risk of progressive disease (chronic kidney disease stages 1-4) with/without nephroprotective therapy. METHODS: This was a prospective,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.